HormonalFDA ApprovedFDA Approved

Leuprolide

Also known as Lupron, Eligard, Leuprorelin

A GnRH agonist suppressing testosterone and estrogen production, approved for prostate cancer, endometriosis, uterine fibroids, and precocious puberty.

FDA Approved - Multiple indications

Regulatory Pathway

Preclinical
Phase I
Phase II
Phase III
Phase IV
Approved

Dosing Protocol

Typical Dose

7.5 mg monthly depot (common)

Frequency

Daily, monthly, or every 3-6 months

Duration

Months to years depending on indication

Community-reported dosing. Individual results vary. Not a medical recommendation.
Typical community protocol: 7.5 mg monthly depot (common) via Intramuscular or subcutaneous depot injection, Daily, monthly, or every 3-6 months. Dose range: 1 mg daily to 45 mg every 6 months. Duration: Months to years depending on indication.

Timing & Administration

Administer via Intramuscular or subcutaneous depot injection. Frequency: Daily, monthly, or every 3-6 months.

Mechanism of Action

Initially stimulates then suppresses gonadotropin release through continuous GnRH receptor stimulation, resulting in reversible medical castration following initial flare.

Research Summary

Evidence level: fda approved. Clinical status: FDA Approved - Multiple indications.

Side Effects & Safety

Important Warnings

  • Tumor flare reaction on initiation
Hot flashes (very common)
injection site reactions
headache
fatigue
depression
bone thinning
tumor flare reaction
cardiovascular risks

References

No references available.